tirzepatide mixture Compounded (GLP-1/GIP) A new study shows that

Wegovy delivers cardiovascular benefits as well, specifically for adults who are overweight or obese and have cardiovascular disease

What this means for MEDVi MEDVi continues to offer compounded tirzepatide as of the time of this writing

These agents slow gastric emptying and intestinal transit, which theoretically could predispose to small intestinal bacterial overgrowth (SIBO)

The data on this is limited for retatrutide since it is newer, but the general pattern with GLP-1 agonists suggests that maintaining weight loss after stopping requires lifestyle modifications regardless of which compound you used

When weight gain occurs despite treatment, it suggests that factors may be interfering with these intended effects or that other physiological processes are at play